With respect to AD, many studies have examined the ability of nAChR α7 agonist treatment to reverse cognitive impairment induced by administration of the nonselective muscarinic AChR antagonist scopolamine. The gene discussed is IGKV2D-24; the disease is Cognitive impairment.